KANT.Kineta, Inc/de
10-Q: Kineta Inc. Faces Going Concern Issues Amidst Failed Funding and Strategic Review
Sentiment:
Quarterly Report
Kineta Inc. is exploring strategic alternatives, including a potential sale or liquidation, due to substantial doubt about its ability to continue as a going concern after a private placement funding failed.
Capital raiseKineta is exploring strategic alternatives that may include, but are not limited to, sale of assets of the Company, a sale of the Company, licensing of assets, a merger, liquidation or other strategic action.Kineta may seek additional funds through equity or debt financings or through collaborations, licensing transactions or other sources that may be identified through the Company's strategic process.
Worse than expectedThe company's cash reserves are critically low, raising substantial doubt about its ability to continue as a going concern.A private placement expected to provide $22.5 million in funding failed to close.The company is not in compliance with Nasdaq listing rules due to a low stock price and negative stockholders' equity.
Summary
- Kineta Inc., a clinical-stage biotechnology company, is facing significant financial challenges, including recurring net losses and negative cash flows.
- As of June 30, 2024, the company had an accumulated deficit of $178.6 million and only $900,000 in unrestricted cash.
- A private placement expected to provide $22.5 million in funding failed to close, exacerbating the company's financial difficulties.
- Kineta is exploring strategic alternatives, including a potential sale of assets, a merger, or liquidation.
- The company has paused or significantly scaled back development of its product candidates due to the lack of funding.
- The company's net loss for the six months ended June 30, 2024, was $12.9 million.
- Kineta has entered into an exclusivity agreement with TuHURA Biosciences, receiving a $5 million payment, with a potential for an additional $300,000, for the rights to acquire its VISTA blocking immunotherapy program.
Sentiment
Score: 2
Explanation: The document paints a dire picture of Kineta's financial situation, with a high risk of liquidation or bankruptcy. The failed private placement and Nasdaq delisting notices further contribute to the negative sentiment.
Positives
- Kineta received a $5 million exclusivity payment from TuHURA Biosciences for its VISTA blocking immunotherapy program.
- The company is actively exploring strategic alternatives to maximize shareholder value.
- Kineta has a pipeline of immunotherapies, including a VISTA blocking antibody and an anti-CD27 agonist antibody, that have potential in the immuno-oncology market.
Negatives
- Kineta has incurred significant net losses and negative cash flows since its inception.
- The company's cash reserves are critically low, raising substantial doubt about its ability to continue as a going concern.
- A private placement expected to provide $22.5 million in funding failed to close.
- Kineta has paused or significantly scaled back its research and development activities.
- The company is not in compliance with Nasdaq listing rules due to a low stock price and negative stockholders' equity.
- The company's trading prices are highly speculative and may not reflect the actual value of its securities.
Risks
- Kineta may not be able to secure additional funding or complete a strategic transaction on acceptable terms.
- The company may be forced to liquidate or file for bankruptcy if it cannot raise sufficient capital.
- The company's stock price is highly speculative and may not reflect the actual value of its securities.
- Kineta is not in compliance with Nasdaq listing rules and may be delisted.
- Geopolitical developments, such as the conflict in Ukraine and the conflict in Israel and the Gaza Strip, may impact the company's operations and financial results.
- The company has material weaknesses in its internal control over financial reporting.
Future Outlook
Kineta is exploring strategic alternatives, including a potential sale or liquidation, due to substantial doubt about its ability to continue as a going concern. The company's future depends on securing additional funding or completing a strategic transaction.
Management Comments
- Management and the Board determined that it was in the best interests of the stockholders to seek a strategic alternative.
- The Company cautions that trading in the Company's securities is highly speculative and poses substantial risks.
- The Company urges extreme caution with respect to existing and future investments in its securities.
Industry Context
The immuno-oncology market is a large and growing market, with sales of approximately $111 billion in 2023 and a forecast to reach $201 billion in 2028. Kineta's focus on developing immunotherapies targeting VISTA and CD27 aligns with this market trend, but the company's financial challenges pose a significant risk to its ability to capitalize on this opportunity.
Comparison to Industry Standards
- Kineta's financial situation is significantly worse than many of its peers in the biotechnology industry, particularly those with clinical-stage assets.
- Many biotech companies at a similar stage of development have secured sufficient funding to continue their clinical programs, while Kineta is facing a potential liquidation.
- The failure of the private placement is a major setback, as it indicates a lack of investor confidence in the company's prospects.
- The company's inability to maintain Nasdaq listing requirements is also a sign of financial distress, as most public biotech companies are able to meet these requirements.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Shawn Iadonato | NA | 2024-03-01 | Termination of employment without cause |
| General Counsel | Pauline Kenny | NA | 2024-03-01 | Termination of employment without cause |
Legal Proceedings
- Kineta has filed a complaint against Growth & Value Development Inc. for breach of contract related to the failed private placement.
- Kineta has filed a complaint against Myron Wolff for breach of contract related to the failed private placement.
Related Party Transactions
- The first closing of the Private Placement occurred on December 16, 2022 and the Company issued 649,346 shares of its common stock and received net proceeds of $7.4 million to investors that are related parties.
- On April 22, 2024, the Company entered into a settlement agreement and mutual release with RLB Holdings Connecticut, LLC, where Raymond Bartoszek, a member of the Board, serves as the Managing Member.
Stakeholder Impact
- Shareholders face a high risk of losing their investment due to the company's financial difficulties and potential liquidation.
- Employees have been impacted by a significant reduction in workforce.
- Customers and partners may be affected by the company's reduced operations and potential liquidation.
- Creditors may face difficulties in recovering outstanding debts.
Next Steps
- Kineta will continue to explore strategic alternatives, including a potential sale or liquidation.
- The company will negotiate with TuHURA Biosciences regarding a potential acquisition of its VISTA blocking immunotherapy program.
- Kineta will monitor its stock price and attempt to regain compliance with Nasdaq listing rules.
- The company will pursue litigation or seek other settlements against the investors for the failure to fund the private placement.
Key Dates
| Date | Description |
|---|---|
| 2020-08-01 | Date of Small Business Administration loan. |
| 2020-10-01 | Date of 2020 notes payable. |
| 2022-12-16 | Date of merger with Yumanity Therapeutics and first closing of private placement. |
| 2023-06-01 | Date of Merck Neuromuscular License Agreement milestone payment. |
| 2024-02-29 | Date of announcement of corporate restructuring and reduction in workforce. |
| 2024-04-15 | Expected date of second closing of private placement, which failed to occur. |
| 2024-04-18 | Date of Nasdaq bid price deficiency letter. |
| 2024-04-22 | Date of settlement agreement with RLB Holdings Connecticut, LLC. |
| 2024-05-23 | Date of Nasdaq stockholders' equity deficiency letter. |
| 2024-06-30 | End of the quarterly period covered by the report. |
| 2024-07-03 | Date of exclusivity agreement with TuHURA Biosciences. |
| 2024-07-31 | Maturity date of 2020 notes and lease agreement. |
| 2024-08-06 | Date of outstanding shares of common stock. |
| 2024-08-08 | Date of filing of the 10-Q report. |
| 2024-10-01 | End date of exclusivity period with TuHURA Biosciences. |
| 2024-10-15 | Deadline to regain compliance with Nasdaq bid price rule. |
Keywords
Kineta, biotechnology, immunotherapy, VISTA, CD27, clinical trials, funding, strategic alternatives, liquidation, bankruptcy, Nasdaq, going concern
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.